The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
ThermoFisher Scientific Patheon Pharma Services
×
Recent searches Clear History
Suggestions
All Results
 Search
 US | EN

Gosselies, Belgium, Europe

Viral vector development and analytical facility

Viral vector services

Thermo Fisher Scientific’s Gosselies facility, located in the heart of Belgium’s largest biotech hub, is dedicated to developing viral vectors (process and analytical) for clinical applications.

The facility has 400 square meters of R&D space, and 380 square meters of classified cGMP space staffed by industry experts in the development of viral vectors, viruses, vaccines, and other therapies. The facility ensures a lean and efficient transfer from viral vector development to cGMP manufacturing.

Gosselies is part of our European network of viral vector sites, which includes Seneffe, Belgium, and part of our global network, including Cambridge and Plainville, MA in the US.

Location Image

16 rue Clément Ader,
6041 Gosselies,
Belgium 
Tel: +32 71 347900

Viral vector manufacturing and development capabilities at Plainville facility

Key Capabilities:

  • Experience in viral vector and virus development for cell and gene therapies, vaccine applications and other therapies.
  • Process and analytical development
  • Broad array of adherent and suspension processes
  • Small- to mid-scale: up to 200L
Facility Offering
Specifications
Process Development
  • Upstream DOE studies in ambr 250
    		•
  • 200L pilot bioreactor and Cell Stack 10
    		•
  • Hyperstack36 adherent process – preclinical
    		•
  • production and scale-up
    		•
  • Clarification optimization
    		•
  • Depth and other filtration methods
    		•
  • TFF concentration and buffer exchange
    		•
  • Varied Chromatography modalities/resins: Affinity, SEC, IEX, HIC, etc.
    		•
  • Viral inactivation/clearance support
    		•
  • Centrifugal separations
    		•
  • Scale down process and Process Characterization
    		•
    Process Characterization
     
  • Process Scale down, process design and process characterization
    		•
    Process Development
  • Assay establishment, customization and/or development
    		•
  • Activity, purity, product quality and yield (DOE) - Qualification & validation of methods
    		•
  • DOE and Pre-clinical material testing -Transfer to QC for testing
    		•

    To learn more about this location, download the site capabilities factsheet.

    Helpful Resources

    Infographic
    Regulatory pathways for CGT and ATMP products
    CGT is one of the world's fastest-growing therapeutic areas today. Instead of treating patients for the rest of their lives, these therapies offer them hope of a cure. In this infographic, we will review three tips for achieving regulatory success.
    Download infographic
    eBook
    Cell and gene therapies in the US vs. the EU: Top five areas of differentiation
    In this eBook we share the five key differences in the drug development and review process for companies hoping to gain market access through US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval—as well as tips for navigating these differences.
    Download eBook
    Blog post
    Product and partnership quality in viral vector manufacturing: Your gene therapy depends on it
    Viral vectors are inherently complex to produce at scale, requiring a laser focus on quality to ensure the efficiency, safety, targeted delivery, and scalability of the gene therapy.
    Read blog
    Article
    From early innovations to commercial triumphs: One viral vector partner for every stage of gene therapy development
    Our article explores the partnership needs of two companies at opposite ends of the continuum for gene therapy development and how both—NysnoBio and bluebird bio—found the support they were looking for to deliver their innovative therapies to patients.
    Download article